Vestmark Advisory Solutions Inc. Sells 656 Shares of Edwards Lifesciences Co. (NYSE:EW)

Vestmark Advisory Solutions Inc. lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 19.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,748 shares of the medical research company’s stock after selling 656 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Edwards Lifesciences were worth $203,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the third quarter valued at approximately $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the third quarter valued at approximately $32,000. Avior Wealth Management LLC raised its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $46,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock worth $2,799,104 over the last quarter. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Evercore ISI lowered their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Truist Financial reissued a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $70.36 on Monday. The stock has a market cap of $41.37 billion, a P/E ratio of 10.10, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The firm’s fifty day simple moving average is $72.26 and its 200 day simple moving average is $70.39. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.